This segment focuses on the research, development, and clinical trials of Buntanetap, an orally administered drug, for the treatment of Alzheimer's disease (AD). The company is conducting Phase 2a clinical trials and is also involved in clinical trials for Alzheimer's disease in Down Syndrome. Research and development activities include ongoing clinical trials, biomarker studies, and exploring innovative combinations for potential future breakthroughs. The therapeutic approach aims to address the unmet medical needs of AD patients by targeting neurodegeneration. Market positioning is based on the potential of Buntanetap to slow or halt the progression of AD. Future opportunities include expanding clinical trials and seeking regulatory approvals. Regulatory and clinical aspects involve navigating FDA guidelines and ensuring patient safety. Partnerships and collaborations may be sought to accelerate clinical development and commercialization.

This segment is dedicated to the development of Buntanetap for the treatment of Parkinson's disease (PD). Research and development activities include Phase 2a clinical trials to evaluate the efficacy and safety of Buntanetap in PD patients. The company utilizes its drug platform to address neurodegeneration, aiming to improve the lives of individuals affected by PD. The segment's market positioning is based on the potential of Buntanetap to provide therapeutic benefits for PD patients. Future opportunities include expanding clinical trials and seeking regulatory approvals. Regulatory and clinical aspects involve adhering to FDA guidelines and ensuring patient safety. Partnerships and collaborations may be pursued to advance clinical development and commercialization efforts.

This segment focuses on the development of ANVS405 for protecting against traumatic brain injury and stroke. Research and development activities include preclinical studies and clinical trials to assess the efficacy and safety of ANVS405. The company is leveraging its expertise in neurodegeneration to address the unmet medical needs of patients suffering from acute brain and nerve injuries. The segment's market positioning is based on the potential of ANVS405 to provide therapeutic benefits for patients with acute brain and nerve injuries. Future opportunities include expanding clinical trials and seeking regulatory approvals. Regulatory and clinical aspects involve adhering to FDA guidelines and ensuring patient safety. Partnerships and collaborations may be sought to accelerate clinical development and commercialization.